Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 194 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ethinyl estradiol Clear all
Completed Phase 2 Interventional

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

NCT00033358
View directory record Official record
Conditions
Endometrial Cancer
Interventions
medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

NCT01360996
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3 mg DRSP/20 μg EE
Drug
Lead sponsor
Woman's
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882
View directory record Official record
Conditions
Healthy
Interventions
DR-1021, Mircette®, Kariva®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

NCT06310616
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Loestrin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00932321
View directory record Official record
Conditions
Prevention of Pregnancy
Interventions
Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Oral Contraceptive, Loestrin 1.5/30
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 21, 2026, 10:40 AM EDT
Withdrawn Phase 4 Interventional

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

NCT01941134
View directory record Official record
Conditions
Bariatric Surgery Candidate, Contraception
Interventions
ethinyl estradiol-levonorgestrel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

NCT00996580
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
DR-103
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
3,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
94
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions
EE 30mcg/LNG 150mcg, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 21, 2026, 10:40 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

NCT02367846
View directory record Official record
Conditions
Other Disorders of Bone Development and Growth
Interventions
Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed No phase listed Observational Results available

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211
View directory record Official record
Conditions
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions
combined oral contraceptives
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 21, 2026, 10:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685
View directory record Official record
Conditions
Drug Interactions
Interventions
BIIB074, OC (ethinyl estradiol and levonorgestrel)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934
View directory record Official record
Conditions
Menstruation Disturbances, Premenstrual Syndrome
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 21, 2026, 10:40 AM EDT